Quick Answer
Propanc Biopharma, Inc. reported Operating Income Loss of -$57.28 million for the year ending 2025.
- Propanc Biopharma, Inc. showed a decrease of -3,628.9% in Operating Income Loss from 2024 to 2025.
- This data is from Propanc Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on September 29, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2017: -$1.44 million | Q1 2018: -$807.1 thousand | Q3 2018: -$448.9 thousand | Q4 2018: -$757.8 thousand | Q1 2019: -$571.7 thousand | Q3 2019: -$909.4 thousand | Q4 2019: -$1.38 million | Q1 2020: -$607.2 thousand | Q3 2020: -$383.2 thousand | Q4 2020: -$274.1 thousand | Q1 2021: -$428.0 thousand | Q3 2021: -$486.0 thousand | Q4 2021: -$403.5 thousand | Q1 2022: -$502.2 thousand | Q3 2022: -$572.8 thousand | Q4 2022: -$608.0 thousand | Q1 2023: -$386.2 thousand | Q3 2023: -$417.2 thousand | Q4 2023: -$438.1 thousand | Q1 2024: -$420.9 thousand | Q3 2024: -$290.8 thousand | Q4 2024: -$213.4 thousand | Q1 2025: -$53.13 million | Q3 2025: -$4.67 million | Q4 2025: -$3.65 million.
- Over the full 15 years of available data (2011 to 2025), Propanc Biopharma, Inc.'s Operating Income Loss has declined by 2,462.4%.
- Historical annual values: Fiscal year 2025: -$57.28 million | Fiscal year 2024: -$1.54 million | Fiscal year 2023: -$1.78 million | Fiscal year 2022: -$1.99 million | Fiscal year 2021: -$1.81 million | Fiscal year 2020: -$3.49 million | Fiscal year 2019: -$2.61 million | Fiscal year 2018: -$3.96 million | Fiscal year 2017: -$5.74 million | Fiscal year 2016: -$6.90 million | Fiscal year 2015: -$1.71 million | Fiscal year 2014: -$761.2 thousand | Fiscal year 2013: -$1.36 million | Fiscal year 2012: -$11.59 million | Fiscal year 2011: -$2.24 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: